SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 03, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on April 1, 2026 (the 'Grant Date”), ORIC granted a total of 80,000 non-qualified stock options and 15,000 restricted stock units to one new non-executive employee who began their employment with ORIC in March 2026.
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
